Authors
Yuexuan Chen, Wenting Bai, Han Zhao, Fangfei Liu, Simeng Lv, Guanming Guo, Jiarui Zhang, Jiahang Lou, Zhihua Cai, Xiangwei Xu, Wenhai Huang
Published in
European journal of medicinal chemistry. Volume 322. Pages 119541. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
KRAS is one of the most frequently mutated oncogenes driving diverse malignancies, yet it has long been deemed "undruggable" due to the absence of a deep binding pocket. In recent years, breakthroughs have been achieved with covalent inhibitors targeting specific mutations, yet drug resistance remains a major challenge. PROTAC technology offers a new approach for overcoming drug resistance through the direct degradation of mutant proteins. Although still in the early stages of development, mutation-specific degraders derived from various KRAS inhibitors have demonstrated potent efficacy against specific mutant forms. However, they face the same coverage limitations as traditional inhibitors. Consequently, pan-KRAS degraders-a strategy that does not rely on specific mutational states and can in principle eliminate all KRAS variants as well as the wild-type protein-have attracted significant attention. This review provides a systematic overview of the design strategies, molecular development, and preclinical progress of KRAS degraders, and discusses the current challenges and future directions.
PMID:
43063568
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0